Invesaro

Stocks KBLB Financial statements

Financial statements

Kraig Biocraft Laboratories, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Kraig Biocraft Laboratories, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue0.030.10.4
Research and development0.40.260.150.220.090.20.180.240.160.17
General and administrative1.741.220.521.413.521.50.831.451.751.96
Operating expenses2.982.251.362.624.532.762.122.613.073.37
Operating income-2.95-2.16-0.96-2.62-4.53-2.76-2.12-2.61-3.07-3.37
Interest expense0.140.180.230.290.010.240.150.480.530.57
Interest income0.01
Other non-operating income-0.13-0.18-0.21-0.29-0.44-5.29-1.72-0.41-0.32-0.25
Pre-tax income-3.07-2.33-1.17-2.91-4.97-8.05-3.84-3.03-3.4-3.62
Income tax000
Net income-3.07-2.33-1.17-2.91-4.97-8.05-3.84-3.03-3.4-3.62
EBITDA-2.93-2.14-0.93-2.59-4.51-2.73-2.09-2.59-3.05-3.35
EPS, basic0.000.000.000.00-0.01-0.010.000.000.000.00
EPS, diluted0.000.000.000.00-0.01-0.010.000.000.000.00
Shares, basic (weighted)7447918178368498789741,0331,0381,059
Shares, diluted (weighted)7447918178368498789741,0331,0381,059

Balance sheet

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash and equivalents0.30.020.010.130.822.363.862.550.671.79
Short-term investments000
Receivables0.030.03
Inventory0.010.010.010.03
Other current assets000.010.0300.010.020.010.060.05
Total current assets0.330.050.020.160.822.373.982.570.741.87
Property, plant and equipment0.050.060.050.120.090.110.090.070.040.03
Lease right-of-use assets00.470.370.10.060.10.090.17
Total assets0.380.110.070.751.283.024.573.231.512.57
Accounts payable0.510.680.790.560.60.590.54
Accrued liabilities2.122.673.350.11
Total current liabilities2.743.494.535.587.458.168.078.899.6110.4
Lease liabilities00.370.250.060.020.050.040.12
Total liabilities2.743.494.536.147.858.328.098.949.6510.6
Paid-in capital2.571.962.042.415.839.8910.811.412.312.4
Retained earnings-23.4-25.7-26.9-29.8-34.8-42.8-46.7-49.7-53.1-56.7
Shareholders' equity-2.36-3.38-4.46-5.39-6.57-5.3-3.52-5.71-8.15-8
Total equity-2.36-3.38-4.46-5.39-6.57-5.3-3.52-5.71-8.15-8
Total liabilities and equity0.380.110.070.751.283.024.573.231.512.57
Shares outstanding774817817

Cash flow statement

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-3.07-2.33-1.17-2.91-4.97-8.05-3.84-3.03-3.4-3.62
Depreciation and amortization0.020.020.030.030.030.030.030.030.030.03
Stock-based compensation0.09
Change in receivables-0.030.010.03
Change in inventory-0.01-0-0.02
Change in payables-0.020.160.14
Cash from operations-1.01-0.73-0.24-1.09-1.25-1.8-1.89-1.24-1.84-1.79
Capital expenditures-0-0.03-0.01-0.1-0.1-0.01-0.01-0-0.01
Purchases of investments-0.45
Cash from investing-0-0.03-0.01-0.1-0.55-0.01-0.01-00.44
Debt repaid-0.02-0.04-0.05-0.06-0.06-0.04-0.13
Stock issued1.030.4501
Cash from financing1.080.480.241.31.953.893.4-0.06-0.042.47
Net change in cash0.06-0.28-00.110.691.541.51-1.31-1.881.12
Free cash flow-1.01-0.76-0.25-1.19-1.9-1.89-1.25-1.84-1.79
Interest paid000
Income taxes paid000

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.07 on September 28, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-97.1%Net income / average total assets.

Growth

MetricValueHow it is calculated
Total assets growth, 1y70.4%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-17.5%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y15.0%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y2.0%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y2.8%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y4.5%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.33xCurrent assets / current liabilities.
Quick ratio0.31x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.31x(Cash + short-term investments) / current liabilities.
Liabilities / assets258.0%Total liabilities / total assets.
Interest coverage-6.27xOperating income / interest expense.
Working capital-$7.3MCurrent assets - current liabilities.
Tangible book value-$6.8MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$0.00Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share-$0.00Free cash flow / diluted weighted shares.
Operating cash flow per share-$0.00Cash from operations / diluted weighted shares.
Book value per share-$0.01Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$0.01Tangible book value / shares outstanding.
Cash per share$0.00(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$75.9MShare price x shares outstanding.
Enterprise value$72.5MMarket cap + total debt - cash - short-term investments.
FCF yield-2.7%Free cash flow / market cap.
Earnings yield-5.5%Net income / market cap (the inverse of P/E).
Was Kraig Biocraft Laboratories, Inc. profitable in fiscal 2025?

No. It reported a net loss of $3.6M.

How much free cash flow did Kraig Biocraft Laboratories, Inc. generate in fiscal 2025?

Cash from operations of $1.8M minus capital expenditures of $5.4K left free cash flow of -$1.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Kraig Biocraft Laboratories, Inc.